Search

Your search keyword '"Bjorkholm, M"' showing total 118 results
Start Over Author "Bjorkholm, M"
118 results on '"Bjorkholm, M"'

1. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden

Author

Hultcrantz, M., Landtblom, A. Ravn, Andreasson, B., Samuelsson, Jan, Dickman, P. W., Kristinsson, S. Y., Bjorkholm, M., Andersson, T. M-L, Hultcrantz, M., Landtblom, A. Ravn, Andreasson, B., Samuelsson, Jan, Dickman, P. W., Kristinsson, S. Y., Bjorkholm, M., and Andersson, T. M-L

Abstract

Background The reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers., Funding Agencies|Karolinska InstitutetKarolinska Institutet; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748, P30 CA008748]; Stockholm County CouncilStockholm County Council; Swedish Research CouncilSwedish Research Council; Blodcancerfonden; Cancer Research Foundations of Radiumhemmet

Published
2020
Full Text
View/download PDF

2. Risk of haematopoietic cancer in patients with inflammatory bowel disease

Author

Askling, J., Brandt, L., Lapidus, A., Karlen, P., Bjorkholm, M., Lofberg, R., and Ekbom, A.

Subjects
Ulcerative colitis -- Complications and side effects, Lymphomas -- Risk factors, Leukemia -- Risk factors, Crohn's disease -- Complications and side effects, Health
Published
2005

4. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden

Author

Gunnarsson, N., Höglund, Martin, Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, Ulla, Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Höglund, Martin, Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, Ulla, Wadenvik, H., Richter, J., and Sjalander, A.

Published
2017
Full Text
View/download PDF

7. Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma

Author

University of Helsinki, Clinicum, Pauly, F., Fjorden, K., Leppa, S., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. Moller, Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M., Wingren, C., University of Helsinki, Clinicum, Pauly, F., Fjorden, K., Leppa, S., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. Moller, Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M., and Wingren, C.

Published
2016

9. MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS : A POPULATION BASED-STUDY

Author

Jonsdottir, G., Lund, S. H., Landgren, O., Bjorkholm, M., Turesson, I., Wahlin, Anders, Blimark, C., Hultcrantz, M., Porwit, A., Kristinsson, S. Y., Jonsdottir, G., Lund, S. H., Landgren, O., Bjorkholm, M., Turesson, I., Wahlin, Anders, Blimark, C., Hultcrantz, M., Porwit, A., and Kristinsson, S. Y.

Published
2014

15. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients : results of a phase II Nordic Lymphoma Group study

Author

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundström, Christer, Karjalainen-Lindsberg, M. -L, Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., Eriksson, M., Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundström, Christer, Karjalainen-Lindsberg, M. -L, Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., and Eriksson, M.

Abstract

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Published
2013
Full Text
View/download PDF

17. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

Author

Bjorkholm, M., Derolf, A.R., Hultcrantz, M., Kristinsson, S.Y., Ekstrand, C., Goldin, L.R., Andreasson, B., Birgegard, G., Linder, O., Malm, Claes, Markevarn, B., Nilsson, L., Samuelsson, J., Granath, F., Landgren, O., Bjorkholm, M., Derolf, A.R., Hultcrantz, M., Kristinsson, S.Y., Ekstrand, C., Goldin, L.R., Andreasson, B., Birgegard, G., Linder, O., Malm, Claes, Markevarn, B., Nilsson, L., Samuelsson, J., Granath, F., and Landgren, O.

Abstract

Purpose: Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Using population-based data from Sweden, we assessed the role of MPN treatment and subsequent AML/MDS risk with special focus on the leukemogenic potential of hydroxyurea (HU). Methods: On the basis of a nationwide MPN cohort (N = 11,039), we conducted a nested case-control study, including 162 patients (153 and nine with subsequent AML and MDS diagnosis, respectively) and 242 matched controls. We obtained clinical and MPN treatment data for all patients. Using logistic regression, we calculated odds ratios (ORs) as measures of AML/MDS risk. Results: Forty-one (25%) of 162 patients with MPNs with AML/MDS development were never exposed to alkylating agents, radioactive phosphorous (P32), or HU. Compared with patients with who were not exposed to HU, the ORs for 1 to 499 g, 500 to 999 g, more than 1,000 g of HU were 1.5 (95% CI, 0.6 to 2.4), 1.4 (95% CI, 0.6 to 3.4), and 1.3 (95% CI, 0.5 to 3.3), respectively, for AML/MDS development (not significant). Patients with MPNs who received P32 greater than 1,000 MBq and alkylators greater than 1 g had a 4.6-fold (95% CI, 2.1 to 9.8; P = .002) and 3.4-fold (95% CI, 1.1 to 10.6; P = .015) increased risk of AML/MDS, respectively. Patients receiving two or more cytoreductive treatments had a 2.9-fold (95% CI, 1.4 to 5.9) increased risk of transformation. Conclusion: The risk of AML/MDS development after MPN diagnosis was significantly associated with high exposures of P32 and alkylators but not with HU treatment. Twenty-five percent of patients with MPNs who developed AML/MDS were not exposed to cytotoxic therapy, supporting a major role for nontreatment-related factors. © 2011 by American Society of Clinical Oncology.

Published
2011
Full Text
View/download PDF

19. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Author

Vianelli, N., primary, Palandri, F., additional, Polverelli, N., additional, Stasi, R., additional, Joelsson, J., additional, Johansson, E., additional, Ruggeri, M., additional, Zaja, F., additional, Cantoni, S., additional, Catucci, A. E., additional, Candoni, A., additional, Morra, E., additional, Bjorkholm, M., additional, Baccarani, M., additional, and Rodeghiero, F., additional

Published
2012
Full Text
View/download PDF

22. Granulocyte-macrophage colony-stimulating factor to increase efficacy ofmitoxantrone, etoposide and cytarabine in previously untreated elderlypatients with acute myeloid leukaemia: a Swedish multicentre randomizedtrial.

Author

Lofgren, C, Paul, C, Astrom, M, Hast, R, Hedenius, M, Lerner, R, Liliemark, J, Nilsson, I, Rodjer, S, Simonsson, B, Stockelberg, D, Tidefelt, U, Bjorkholm, M, Lofgren, C, Paul, C, Astrom, M, Hast, R, Hedenius, M, Lerner, R, Liliemark, J, Nilsson, I, Rodjer, S, Simonsson, B, Stockelberg, D, Tidefelt, U, and Bjorkholm, M

Published
2004

25. No benefit from adding GM-CSF to induction chemotherapy in transformingmyelodysplastic syndromes: better outcome in patients with lessproliferative disease.

Author

Hast, R, Hellstrom-Lindberg, E, Ohm, L, Bjorkholm, M, Celsing, F, Dahl, IM, Dybedal, I, Gahrton, G, Lindberg, G, Lerner, R, Linder, O, Lofvenberg, Eva, Nilsson-Ehle, H, Paul, C, Samuelsson, J, Tangen, JM, Tidefelt, U, Turesson, Ingela, Wahlin, A, Wallvik, J, Winquist, I, Oberg, G, Bernell, P, Hast, R, Hellstrom-Lindberg, E, Ohm, L, Bjorkholm, M, Celsing, F, Dahl, IM, Dybedal, I, Gahrton, G, Lindberg, G, Lerner, R, Linder, O, Lofvenberg, Eva, Nilsson-Ehle, H, Paul, C, Samuelsson, J, Tangen, JM, Tidefelt, U, Turesson, Ingela, Wahlin, A, Wallvik, J, Winquist, I, Oberg, G, and Bernell, P

Published
2003

27. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined withdaunorubicin and cytarabine in patients with relapsed and primaryrefractory acute myeloid leukemia.

Author

Gruber, A, Bjorkholm, M, Brinch, L, Evensen, S, Gustavsson, B, Hedenus, M, Juliusson, G, Lofvenberg, E, Nesthus, I, Simonsson, B, Sjo, M, Stenke, L, Tangen, JM, Tidefelt, U, Uden, AM, Paul, C, Liliemark, J, Gruber, A, Bjorkholm, M, Brinch, L, Evensen, S, Gustavsson, B, Hedenus, M, Juliusson, G, Lofvenberg, E, Nesthus, I, Simonsson, B, Sjo, M, Stenke, L, Tangen, JM, Tidefelt, U, Uden, AM, Paul, C, and Liliemark, J

Published
2003

28. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice

Author

Beran M, Pisa P, Kantarjian H, Anna Porwit, and Bjorkholm M

Subjects
Herpesvirus 4, Human, Cell Survival, DNA, Neoplasm, Mice, SCID, Polymerase Chain Reaction, Drug Resistance, Multiple, HLA-DQ alpha-Chains, Immunophenotyping, Disease Models, Animal, Mice, Leukemia, Myeloid, HLA-DQ Antigens, Acute Disease, Tumor Cells, Cultured, Animals, Humans, Female, Philadelphia Chromosome, Neoplasm Transplantation
Abstract

Drug resistance is a critical problem in the therapy of hematologic malignancies. Recent advances in the transplantation of human normal and transformed hematopoietic cells into severe combined immunodeficient (SCID) mice provide an opportunity to study the biologic and molecular events that mediate resistance. We studied the engraftment of several human myelogenous leukemia cell lines sensitive and resistant to amsacrine (mAMSA), vincristine, hycamptamine, methotrexate, or doxorubicine (KBM3/AMSA, K562/Vcr, HL60/Hy10, K562/MTX, HL60/Dox). The distribution and growth potential of these cells was evaluated using molecular and histologic techniques. Inoculation of 2 x 10(7) leukemic cells led to manifestation of disease, and subsequent tissue analysis showed evidence of leukemia. The survival of mice varied from 21 to 135 days. Terminally, the animals showed symptoms of wasting, development of local tumors, or both. Massive leukemic dissemination with infiltration of bone marrow and various organs including lungs, spleen, liver, ovaries, and brain was detected in most cases. No differences were observed in the tissue distribution of sensitive as compared to resistant leukemia cells. These findings demonstrated that human leukemic cells retain, in SCID mice, the clinico-pathologic picture of the original disease in humans. The development of numerous drug-resistant phenotypes in vitro does not alter the subsequent behavior of resistant cells in vivo when compared with sensitive counterparts. The levels of resistance are not modified by passage through SCID mice. This model offers an opportunity for developing new preclinical in vivo systems for modulation of drug resistance, and the combination of this in vivo model with gene transfer methods will also provide an important system for testing the molecular alterations involved in drug resistance and leukemic progression.

Published
1994

31. Intensive chemotherapy in patients with chronic myelogenous leukaemia(CML) in accelerated or blastic phase--a report from the Swedish CMLGroup.

Author

Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, Bjorkholm, M, Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, and Bjorkholm, M

Published
2002

32. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemiatreated with intensive chemotherapy.

Author

Oberg, G, Killander, A, Bjoreman, M, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Lerner, R, Liliemark, J, Mattson, S, Paul, C, Simonsson, B, Stalfelt, AM, Stenke, L, Tidefelt, U, Uden, AM, Bjorkholm, M, Oberg, G, Killander, A, Bjoreman, M, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Lerner, R, Liliemark, J, Mattson, S, Paul, C, Simonsson, B, Stalfelt, AM, Stenke, L, Tidefelt, U, Uden, AM, and Bjorkholm, M

Published
2002

33. High-dose cytarabine in upfront therapy for adult patients with acutelymphoblastic leukaemia.

Author

Hallbook, H, Simonsson, B, Ahlgren, T, Bjorkholm, M, Carneskog, J, Grimfors, G, Hast, R, Karlsson, K, Kimby, E, Lerner, R, Linder, O, Linderholm, M, Lofvenberg, E, Malm, C, Nilsson, PG, Paul, C, Stenke, L, Stockelberg, D, Tidefelt, U, Turesson, I, Uden-Blome, AM, Vilen, L, Wahlin, A, Winquist, I, Smedmyr, B, Hallbook, H, Simonsson, B, Ahlgren, T, Bjorkholm, M, Carneskog, J, Grimfors, G, Hast, R, Karlsson, K, Kimby, E, Lerner, R, Linder, O, Linderholm, M, Lofvenberg, E, Malm, C, Nilsson, PG, Paul, C, Stenke, L, Stockelberg, D, Tidefelt, U, Turesson, I, Uden-Blome, AM, Vilen, L, Wahlin, A, Winquist, I, and Smedmyr, B

Published
2002

40. Activation of Telomerase by Human Cytomegalovirus

Author

Straat, K., primary, Liu, C., additional, Rahbar, A., additional, Zhu, Q., additional, Liu, L., additional, Wolmer-Solberg, N., additional, Lou, F., additional, Liu, Z., additional, Shen, J., additional, Jia, J., additional, Kyo, S., additional, Bjorkholm, M., additional, Sjoberg, J., additional, Soderberg-Naucler, C., additional, and Xu, D., additional

Published
2009
Full Text
View/download PDF

44. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

Author

Xu, DW, Wang, Q, Gruber, A, Bjorkholm, M, Chen, ZG, Zaid, A, Selivanova, G, Peterson, C, Wiman, KG, Pisa, P, Xu, DW, Wang, Q, Gruber, A, Bjorkholm, M, Chen, ZG, Zaid, A, Selivanova, G, Peterson, C, Wiman, KG, and Pisa, P

Abstract

The p53 tumor suppressor protein inhibits the formation of tumors through induction of cell cycle arrest and/or apoptosis, In the present study we demonstrated that p53 is also a powerful inhibitor of human telomerase reverse transcriptase (hTERT), a key component for telomerase, Activation of either exogenous temperature-sensitive (ts) p53 in BL41 Burkitt lymphoma cells or endogenous wild type (wt) p53 at a physiological level in MCF-7 breast carcinoma cells triggered a rapid downregulation of hTERT mRNA expression, independently of the induction of the p53 target gene p21, Co-transfection of an hTERT promoter construct with wt p53 but not mutant p53 in HeLa cells inhibited the hTERT promoter activity. Furthermore, the activation of the hTERT promoter in Drosophila Schneider SL2 cells was completely dependent on the ectopic expression of Sp1 and was abrogated by wt p53, Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex. Since activation of telomerase, widely observed in human tumor cell lines and primary tumors, is a critical step in tumorigenesis, wt p53-triggered inhibition of hTERT/telomerase expression may reflect yet another mechanism of p53-mediated tumor suppression. Our findings provide new insights into both the biological function of p53 and the regulation of hTERT/telomerase expression.

Published
2000

46. Intensive treatment in order to minimize the ph-positive clone in CML

Author

Simonsson, B, Oberg, G, Bjoreman, M, Bjorkholm, M, Carneskog, J, Gahrton, G, Hast, R, Lang-Nielsen, J, Lofvenberg, E, Malm, C, Turesson, I, Uden, A-M, Vilen, L, Weis-Bjerrum, O, Simonsson, B, Oberg, G, Bjoreman, M, Bjorkholm, M, Carneskog, J, Gahrton, G, Hast, R, Lang-Nielsen, J, Lofvenberg, E, Malm, C, Turesson, I, Uden, A-M, Vilen, L, and Weis-Bjerrum, O

Published
1996

47. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support

Author

Johnsen, H E, Bjorkstrand, B, Carlson, K, Gruber, A, Blystad, A, Fast, A, Boesen, A M, Bjorkholm, M, Sallerfors, B, Ruutu, T, Carneskog, J, Malm, A, Geisler, C, Lehtinen, M, Schroder, H, Brinch, L, Remes, K, Tidefelt, U, Heilman, C, Hornsten, P, Thorling, K, Daugaard, G, Johnsen, H E, Bjorkstrand, B, Carlson, K, Gruber, A, Blystad, A, Fast, A, Boesen, A M, Bjorkholm, M, Sallerfors, B, Ruutu, T, Carneskog, J, Malm, A, Geisler, C, Lehtinen, M, Schroder, H, Brinch, L, Remes, K, Tidefelt, U, Heilman, C, Hornsten, P, Thorling, K, and Daugaard, G

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results